All In Biotech

Drug Trial Radar · NCT05588323

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

A Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment With Opioids

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jan 4, 2023

Primary completion

Jun 15, 2028

Study completion Jun 15, 2028

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Oct 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric participants who are receiving or about to receive opioids.

Conditions

  • Opioid-Induced Constipation (OIC)

Interventions

  • NaldemedineDrug

    Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of Naldemedine and Nor-naldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  2. Time to Achieve Maximum Plasma Concentration (Tmax) of Naldemedine and Nor-naldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  3. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of Naldemedine and Nor-naldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  4. AUC Extrapolated From Time Zero to Infinity (AUC0-inf) of Naldemedine and Nor-naldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  5. Terminal Elimination Rate Constant (λz) of Naldemedine and Nor-naldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  6. Terminal Elimination Half-life (t1/2,z) of Naldemedine and Nor-naldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  7. Apparent Total Clearance (CL/F) of NaldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  8. Mean Residence Time (MRT) of NaldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  9. Apparent Volume of Distribution in the Terminal Phase (Vz/F) of NaldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  10. Metabolic Ratio of Cmax of Nor-naldemedine to Cmax of Naldemedine (MRM/U, Cmax) for Nor-naldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose
  11. Metabolic Ratio of AUC of Nor-naldemedine to AUC of Naldemedine (MRM/U, AUC) for Nor-naldemedineTime frame: Day 1: 0.5, 1, 5, and 12 hours postdose; Day 2: 24 hours post Day 1 dose, before administering the Day 2 dose; Day 7 (Cohort 1 only): Predose and 1 hour postdose

Locations

16 sites in 8 countries. Site status is shown where the registry gives one.

  • University Center Mother Theresa , Hospital - Onco-hematology department

    Tirana, Albania · Not yet recruiting

  • Yeolyan Hematology. , and Oncology Center -

    Yerevan, Armenia · Recruiting

  • CHU Saint-Pierre Clinical Trials Unit

    Brussels, Belgium · Completed

  • Universitair Ziekenhuis Brussel (UZBrussel) - Department of Anesthesiology and Perioperative Medicine

    Brussels, Belgium · Completed

  • University Hospitals Leuven Pediatrisch hemato-oncology

    Leuven, Belgium · Completed

  • University Clinical Hospital , Mostar

    Mostar, Bosnia and Herzegovina · Recruiting

  • Chu de Caen

    Caen, France · Completed

  • Hôpital Béclère Service de Pédiatrie Centre de Référence des Maladies Héréditaires du Métabolisme Hépatique (CRMHMH)

    Clamart, France · Completed

  • Hôpital Jeanne de Flandre Antenne du CIC pédiatrique - Niveau 0 CHU de Lille

    Lille, France · Completed

  • Hôpital Armand Trousseau Service Hématologie et Oncologie Pédiatrique

    Paris, France · Completed

  • Instituto Nazionale dei Tumori

    Milan, Italy · Completed

  • Citta della Salute e della Scienza di Torino

    Torino, Italy · Completed

  • Maternal and Child Health Institute IRCCS Burlo Garofolo, Pain and pediatric palliative care service

    Trieste, Italy · Completed

  • National Center for Child Health and Development

    Tokyo, Japan · Not yet recruiting

  • PHI University Clinic for Children's , Surgery

    Skopje, North Macedonia · Recruiting

  • University Clinic for Childrens Diseases , Department of Oncology, Hematology and , Malignant Hemopathy

    Skopje, North Macedonia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.